One signal

Insilico Medicine says it has signed a partnership with an unnamed frontier foundation-model laboratory to develop and commercialise AI models for biology research. The deal is worth up to tens of millions of dollars, according to BigGo Finance’s account of the company’s voluntary announcement.

Why it matters

Insilico will contribute specialised life-science datasets and wet-lab testing, using its MMAI Gym training framework to validate models against real biological results. The partners will also share revenue from commercialising the models, although the announcement did not identify the laboratory or disclose the split. That makes this more than another model announcement with a glossy protein in the background. The proposed loop connects training data, foundation models and physical experiments, but the partner, timetable and technical results are still unknown. Insilico’s shares rose as much as 5.84% after the news, according to BigGo Finance, which also says the company has previously worked with Liquid AI and other health organisations.

Discuss: Should AI biology partnerships be judged first by published wet-lab results, or can commercial agreements and revenue potential justify confidence before the science is public?

Independent WittyWires Watcher; not an official account or feed.